Crossmark

Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules

Crossref DOI link: https://doi.org/10.1038/srep28912

Published Online: 2016-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Davtyan, Hayk

Zagorski, Karen

Rajapaksha, Harinda

Hovakimyan, Armine

Davtyan, Arpine

Petrushina, Irina

Kazarian, Konstantin

Cribbs, David H.

Petrovsky, Nikolai

Agadjanyan, Michael G.

Ghochikyan, Anahit
License Information

Text and Data Mining valid from 2016-07-01

Version of Record valid from 2016-07-01
More Information

Article History

Received: 19 November 2015

Accepted: 9 May 2016

First Online: 1 July 2016

Competing interests

: N.P. is a Director and H.R. an employee of Vaxine Pty Ltd, the developer of the Advax adjuvant technology. M.G.A. is co-founder of Neuroimmune that licensed MultiTEP vaccine platform technology from the Institute for Molecular Medicine. The remaining author(s) declare no financial and commercial conflict of interests.

Document is current

Any future updates will be listed below